FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Gayer Charles K					2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX]								(Che	ck all applica Director	ible)	10% Owner		ner
(Last) 4505 EM SUITE 2	PEROR B	First) LVD.	(Middle)		3. Date 12/19/	of Earliest 2024	Transa	iction (Mo	nth/E	Day/Year)				below)		nercia	below)	
(Street) DURHAM NC 27703 (City) (State) (Zip)						Í				(Month/Da	,		Line)	Form file Person	ed by One	e Repo	(Check App rting Person One Report	
			able I - Nor						Dis					_				
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 3)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			or 4 and 5)	5. Amount Securities Beneficial Owned Fo	ly	Form	: Direct Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership
							Code	v	Amount	(A) (D)	or [Price	Reported Transaction (Instr. 3 ar	tion(s)			(Instr. 4)	
Common Stock			İ	12/19/2	2024			Α		125,950	O ⁽¹⁾ A		\$ <mark>0</mark>	426,	,007		D	
Common Stock			12/19/2024				F		2,461	(2) I)	\$7.39	423,546			D		
			Table II -							osed of, convertil				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code (Instr.		Derivative		6. Date Exercisable Expiration Date (Month/Day/Year)		of Securitie		ities ng re Sec		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
				Code	y V	(A)		Date Exercisabl		Expiration Date	Title	or Nu	ount mber Shares		Transaction(s) (Instr. 4)			
Emp. Stock Option	\$7.39	12/19/2024		A		260,950	1	2/19/2025	(3)	12/19/2034	Common	26	0,950	\$0	260,9	50	D	

Explanation of Responses:

(Right to Buy)

- 1. Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- 2. Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person

3. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of 12/2<u>3/2024</u> attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.